Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Chemo-Sensitive Relapsed Small Cell Lung Cancer
NCT00470054Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2007
- Primary completion
- Feb 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoint: 6 Week Progression Free Survival. Started Apr 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00470054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00470054.